{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:02:23Z","timestamp":1792072943134,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"fondazione cariplo fondazione veronesi","award":["1833073"],"award-info":[{"award-number":["1833073"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Chronic plaque psoriasis is associated with the presence of non-alcoholic fatty liver disease (NAFLD), but the magnitude of this association remains currently uncertain. We aimed to investigate the magnitude of the association between psoriasis and the risk of prevalent and incident NAFLD, and to assess whether psoriasis severity and\/or psoriatic arthritis are associated with a greater risk of NAFLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic review and meta-analysis of observational studies evaluating the association between psoriasis and NAFLD, as diagnosed by imaging or International Classification of Diseases codes was performed. Literature search on PubMed, Scopus and Web of Science on May 3, 2021 was undertaken. Studies using liver biopsy were not available. For the meta-analysis, the random-effects modelling was adopted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 15 observational (case\u2013control and cross-sectional) studies for a total of 249,933 patients with psoriasis (49% with NAFLD) and 1,491,402 controls (36% with NAFLD). Psoriasis was associated with prevalent NAFLD (<jats:italic>n<\/jats:italic>\u2009=\u200911 studies; pooled random-effects odds ratio [OR] 1.96, 95% CI 1.70\u20132.26; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200997%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Psoriatic patients with NAFLD had a higher mean psoriasis area and severity index (PASI) than their counterparts without NAFLD (<jats:italic>n<\/jats:italic>\u2009=\u20098 studies, pooled weighted mean difference: 3.93, 95% CI 2.01\u20135.84<jats:italic>; I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200988%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). The risk of NAFLD was marginally higher in patients with psoriatic arthritis than in those with psoriasis alone (<jats:italic>n<\/jats:italic>\u2009=\u20095 studies, pooled random-effects OR 1.83, 95% CI 0.98\u20133.43; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200964%, <jats:italic>p<\/jats:italic>\u2009=\u20090.03). Sensitivity analyses did not alter these findings. Funnel plot did not show any significant publication bias. A major limitation of the study was the high degree of heterogeneity across studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Psoriasis is associated with prevalent NAFLD and this risk parallels the severity of psoriasis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-022-01755-0","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T11:04:41Z","timestamp":1644577481000},"page":"1277-1288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6163-6921","authenticated-orcid":false,"given":"F.","family":"Bellinato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"1755_CR1","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E et al (2020) National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 369:m1590","journal-title":"BMJ"},{"key":"1755_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fphar.2020.00117","volume":"11","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Bellinato F, Girolomoni G, Albanesi C (2020) Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol 11:117","journal-title":"Front Pharmacol"},{"key":"1755_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/metabo10100397","volume":"10","author":"G Targher","year":"2020","unstructured":"Targher G (2020) What\u2019s past is prologue: history of nonalcoholic fatty liver disease. Metabolites 10:397","journal-title":"Metabolites"},{"key":"1755_CR4","doi-asserted-by":"publisher","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","volume":"111S","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G (2020) Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 111S:154170","journal-title":"Metabolism"},{"key":"1755_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","volume":"15","author":"QM Anstee","year":"2018","unstructured":"Anstee QM, Mantovani A, Tilg H, Targher G (2018) Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 15:425\u2013439","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1755_CR6","doi-asserted-by":"crossref","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, Tilg H, Byrne CD, Targher G (2020) Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 71(1):156-162","DOI":"10.1136\/gutjnl-2020-323082"},{"key":"1755_CR7","doi-asserted-by":"crossref","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD, Targher G (2021) Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut. gutjnl-2021-324191","DOI":"10.1136\/gutjnl-2021-324191"},{"key":"1755_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/ijms17020217","volume":"17","author":"A Mantovani","year":"2016","unstructured":"Mantovani A, Gisondi P, Lonardo A, Targher G (2016) Relationship between non-alcoholic fatty liver disease and psoriasis: a novel hepato-dermal axis? Int J Mol Sci 17:217","journal-title":"Int J Mol Sci"},{"key":"1755_CR9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/jdv.12847","volume":"29","author":"R Candia","year":"2015","unstructured":"Candia R, Ruiz A, Torres-Robles R, Ch\u00e1vez-Tapia N, M\u00e9ndez-S\u00e1nchez N, Arrese M (2015) Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 29:656\u2013662","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1755_CR10","first-page":"e352","volume":"60","author":"K Phan","year":"2019","unstructured":"Phan K, Onggo J, Charlton O, Smith SD (2019) Relationship between psoriasis and non-alcoholic fatty liver disease\u2014updated systematic review and adjusted meta-analysis. Australas J Dermatol 60:e352\u2013e355","journal-title":"Australas J Dermatol"},{"key":"1755_CR11","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097","journal-title":"PLoS Med"},{"key":"1755_CR12","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-Analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008\u20132012","journal-title":"JAMA"},{"key":"1755_CR13","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P et al (2006) Classification criteria for psoriatic arthritis; development of new criteria from a large international study. Arthritis Rheum 54:2665\u20132673","journal-title":"Arthritis Rheum"},{"key":"1755_CR14","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al, American Gastroenterological Association, American Association for the Study of Liver Diseases, American College of Gastroenterology (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142:1592\u20131609","DOI":"10.1053\/j.gastro.2012.04.001"},{"key":"1755_CR15","doi-asserted-by":"crossref","unstructured":"Wells GA, Shea B, O\u2019Connell D et al (2011) The Newcastle-Ottawa Scale (NOS) for assessing the quality of case-control studies in meta-analyses. Eur J Epidemiol 25:603\u2013605. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 1 Dec 2021","DOI":"10.1007\/s10654-010-9491-z"},{"key":"1755_CR16","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"key":"1755_CR17","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088\u20131101","journal-title":"Biometrics"},{"key":"1755_CR18","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1136\/bmj.315.7121.1533","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Phillips AN (1997) Meta-analysis: principles and procedures. BMJ 315:1533\u20131537","journal-title":"BMJ"},{"key":"1755_CR19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/ced.12672","volume":"40","author":"R Abedini","year":"2015","unstructured":"Abedini R, Salehi M, Lajevardi V, Beygi S (2015) Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol 40:722\u2013727","journal-title":"Clin Exp Dermatol"},{"key":"1755_CR20","first-page":"33","volume":"11","author":"O Awosika","year":"2018","unstructured":"Awosika O, Eleryan MG, Rengifo-Pardo M, Doherty L, Martin LW, Ehrlich A (2018) A case-control study to evaluate the prevalence of nonalcoholic fatty liver disease among patients with moderate-to-severe psoriasis. J Clin Aesthet Dermatol 11:33\u201337","journal-title":"J Clin Aesthet Dermatol"},{"key":"1755_CR21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jhep.2009.04.020","volume":"51","author":"P Gisondi","year":"2009","unstructured":"Gisondi P, Targher G, Zoppini G, Girolomoni G (2009) Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 51:758\u2013764","journal-title":"J Hepatol"},{"key":"1755_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/jdv.13456","volume":"30","author":"P Gisondi","year":"2016","unstructured":"Gisondi P, Barba E, Girolomoni G (2016) Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol 30:282\u2013287","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1755_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1440-0960.2012.00905.x","volume":"53","author":"S Madanagobalane","year":"2012","unstructured":"Madanagobalane S, Anandan S (2012) The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol 53:190\u2013197","journal-title":"Australas J Dermatol"},{"key":"1755_CR24","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jid.2017.10.024","volume":"138","author":"A Ogdie","year":"2018","unstructured":"Ogdie A, Grewal SK, Noe MH, Shin DB, Takeshita J, Chiesa Fuxench ZC et al (2018) Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study. J Investig Dermatol 138:760\u2013767","journal-title":"J Investig Dermatol"},{"key":"1755_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdermsci.2011.03.002","volume":"63","author":"TF Tsai","year":"2011","unstructured":"Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M et al (2011) Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 63:40\u201346","journal-title":"J Dermatol Sci"},{"key":"1755_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jaad.2013.10.044","volume":"70","author":"EA van der Voort","year":"2014","unstructured":"van der Voort EA, Koehler EM, Dowlatshahi EA, Hofman A, Stricker BH, Janssen HL et al (2014) Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55\u00a0years old or older: results from a population-based study. J Am Acad Dermatol 70:517\u2013524","journal-title":"J Am Acad Dermatol"},{"key":"1755_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2340\/00015555-2161","volume":"96","author":"EA van der Voort","year":"2016","unstructured":"van der Voort EA, Koehler EM, Nijsten T, Stricker BH, Hofman A, Janssen HL et al (2016) Increased prevalence of advanced liver fibrosis in patients with psoriasis: a cross-sectional analysis from the Rotterdam study. Acta Derm Venereol 96:213\u2013217","journal-title":"Acta Derm Venereol"},{"key":"1755_CR28","first-page":"00562","volume":"S0190\u20139622","author":"JJ Yang","year":"2021","unstructured":"Yang JJ, Nguyen KA, Fleischman MW, Aly O, Cheng K (2021) Psoriasis in liver disease: associations beyond nonalcoholic fatty liver disease. J Am Acad Dermatol S0190\u20139622:00562\u201300564","journal-title":"J Am Acad Dermatol"},{"key":"1755_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-020-01740-8","author":"A Yousaf","year":"2020","unstructured":"Yousaf A, Raiker R, Davis SM, Gayam S, Zinn Z (2020) Association between psoriasis, psoriatic arthritis and gastrointestinal disease: an exploratory nationwide inpatient sample analysis. Wien Klin Wochenschr. https:\/\/doi.org\/10.1007\/s00508-020-01740-8","journal-title":"Wien Klin Wochenschr"},{"key":"1755_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/ajd.13175","volume":"61","author":"J Magdaleno-Tapial","year":"2020","unstructured":"Magdaleno-Tapial J, Valenzuela-O\u00f1ate C, Ortiz-Salvador JM, Mart\u00ednez-Dom\u00e9nech \u00c1, Garc\u00eda-Legaz-Mart\u00ednez M, Alonso-Carpio M et al (2020) Prevalence of non-alcoholic fatty liver and liver fibrosis in patients with moderate-severe psoriasis: a cross-sectional cohort study. Australas J Dermatol 61:105\u2013109","journal-title":"Australas J Dermatol"},{"key":"1755_CR31","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jhep.2009.06.008","volume":"51","author":"L Miele","year":"2009","unstructured":"Miele L, Vallone S, Cefalo C, La Torre G, Di Stasi C, Vecchio FM et al (2009) Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 51:778\u2013786","journal-title":"J Hepatol"},{"key":"1755_CR32","first-page":"263","volume":"11","author":"K Narayanasamy","year":"2016","unstructured":"Narayanasamy K, Sanmarkan AD, Rajendran K, Annasamy C, Ramalingam S (2016) Relationship between psoriasis and non-alcoholic fatty liver disease. Prz Gastroenterol 11:263\u2013269","journal-title":"Prz Gastroenterol"},{"key":"1755_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/apt.13042","volume":"41","author":"KK Roberts","year":"2015","unstructured":"Roberts KK, Cochet AE, Lamb PB, Brown PJ, Battafarano DF, Brunt EM, Harrison SA (2015) The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther 41:293\u2013300","journal-title":"Aliment Pharmacol Ther"},{"key":"1755_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1468-3083.2010.03841.x","volume":"25","author":"KS Wenk","year":"2011","unstructured":"Wenk KS, Arrington KC, Ehrlich A (2011) Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol 25:383\u2013391","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1755_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73:202\u2013209","journal-title":"J Hepatol"},{"key":"1755_CR36","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.tem.2021.04.008","volume":"32","author":"S Lim","year":"2021","unstructured":"Lim S, Kim JW, Targher G (2021) Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 32:500\u2013514","journal-title":"Trends Endocrinol Metab"},{"key":"1755_CR37","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/jid.2010.103","volume":"130","author":"BB Davidovici","year":"2010","unstructured":"Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN et al (2010) Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Investig Dermatol 130:1785\u20131796","journal-title":"J Investig Dermatol"},{"key":"1755_CR38","doi-asserted-by":"publisher","first-page":"e14281","DOI":"10.1111\/dth.14281","volume":"33","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Bellinato F, Bruni M, De Angelis G, Girolomoni G (2020) Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome. Dermatol Ther 33:e14281","journal-title":"Dermatol Ther"},{"key":"1755_CR39","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/14656566.2019.1583207","volume":"20","author":"A Chiricozzi","year":"2019","unstructured":"Chiricozzi A, Gisondi P, Girolomoni G (2019) The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother 20:863\u2013872","journal-title":"Expert Opin Pharmacother"},{"key":"1755_CR40","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/jdv.16004","volume":"34","author":"S Gerdes","year":"2020","unstructured":"Gerdes S, Pinter A, Papavassilis C, Reinhardt M (2020) Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J Eur Acad Dermatol Venereol 34:533\u2013541","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1755_CR41","unstructured":"Tha\u00e7i D, Sch\u00e4kel K, Cornberg M, Sieder C, Bachhuber T, Hillmann E et al. Secukinumab in psoriasis patients with non-alcoholic fatty liver disease: study design and objectives of the PINPOINT trial. In: Poster session presented at: 29th European Academy of Dermatology and Venereology, 29\u201331st October 2020, Virtual Congress"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01755-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-022-01755-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01755-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T12:10:31Z","timestamp":1654776631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-022-01755-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1755"],"URL":"https:\/\/doi.org\/10.1007\/s40618-022-01755-0","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"assertion":[{"value":"25 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F. Bellinato: none declared; P. Gisondi: none declared; A. Mantovani: none declared; G. Girolomoni: none declared; G. Targher: none declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}